Literature DB >> 10194832

Rabipur: a reliable vaccine for rabies protection.

I Vodopija1, Z Baklaić, R Vodopija.   

Abstract

Rabipur, a vaccine propagated on chick embryo fibroblasts, is one of the 'second generation' rabies vaccines produced by cell culture techniques. It compares in tolerance, immunogenicity and efficacy with the human diploid cell culture vaccines and is significantly more economical to be produced. It has proven to be an excellent vaccine, particularly when employed by the 2-1-1 schedule vaccination. This approach combines economy of vaccine with increased safety of treatment. Rabipur was investigated in all immunological parameters and can be recommended as a vaccine of choice for postexposure rabies treatment.

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10194832     DOI： 10.1016/s0264-410x(98)00427-7

Source DB:  PubMed          Journal:  Vaccine        ISSN： 0264-410X            Impact factor:   3.641


  4 in total

Review 1.  Zagreb regimen, an abbreviated intramuscular schedule for rabies vaccination.

Authors:  Jiangping Ren; Linong Yao; Jimin Sun; Zhenyu Gong
Journal:  Clin Vaccine Immunol       Date:  2014-11-12

2.  Comparative study on the immunogenicity and safety of a purified chick embryo cell rabies vaccine (PCECV) administered according to two different simulated post exposure intramuscular regimens (Zagreb versus Essen).

Authors:  B J Mahendra; Dh Ashwath Narayana; Sharad Agarkhedkar; H S Ravish; B R Harish; Shalaka Agarkhedkar; S N Madhusudana; Ashwin Belludi; Khaleel Ahmed; Rekha Jonnalagedda; Hoshang Vakil; Chiranjiwi Bhusal; Ashwani Kumar Arora
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

3.  Immunogenicity, safety and antibody persistence of a purified vero cell cultured rabies vaccine (Speeda) administered by the Zagreb regimen or Essen regimen in post-exposure subjects.

Authors:  Nianmin Shi; Yibin Zhang; Huizhen Zheng; Zhenggang Zhu; Dingming Wang; Sihai Li; Yuhua Li; Liqing Yang; Junnan Zhang; Yunhua Bai; Qiang Lu; Zheng Zhang; Fengji Luo; Chun Yu; Li Li
Journal:  Hum Vaccin Immunother       Date:  2017-01-25       Impact factor: 3.452

4.  A randomized, placebo-controlled phase I study assessing the safety and immunogenicity of a Pseudomonas aeruginosa hybrid outer membrane protein OprF/I vaccine (IC43) in healthy volunteers.

Authors:  Kerstin Westritschnig; Romana Hochreiter; Gerhard Wallner; Christa Firbas; Michael Schwameis; Bernd Jilma
Journal:  Hum Vaccin Immunother       Date:  2013-09-24       Impact factor: 3.452
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.